4 Drugs Stocks Pushing The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.1%) at 16,065 as of Monday, Dec. 2, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,030 issues advancing vs. 1,883 declining with 116 unchanged.

The Drugs industry currently sits down 0.4% versus the S&P 500, which is unchanged.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.29 (0.5%) to $57.48 on heavy volume. Thus far, 1.4 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $57.29-$57.48 after having opened the day at $57.36 as compared to the previous trading day's close of $57.19.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $69.6 billion and is part of the health care sector. The company has a P/E ratio of 11.1, below the S&P 500 P/E ratio of 17.7. Shares are up 17.5% year to date as of the close of trading on Friday. Currently there are no analysts that rate AstraZeneca a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Forest Laboratories ( FRX) is up $2.68 (5.2%) to $53.99 on heavy volume. Thus far, 2.2 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $52.95-$54.13 after having opened the day at $53.56 as compared to the previous trading day's close of $51.31.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $13.7 billion and is part of the health care sector. Shares are up 45.3% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Forest Laboratories Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Herbalife ( HLF) is up $1.79 (2.6%) to $71.47 on light volume. Thus far, 706,624 shares of Herbalife exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $69.24-$71.81 after having opened the day at $69.68 as compared to the previous trading day's close of $69.68.

Herbalife Ltd., through its subsidiaries, produces and distributes weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products worldwide. Herbalife has a market cap of $7.1 billion and is part of the consumer goods sector. The company has a P/E ratio of 14.4, below the S&P 500 P/E ratio of 17.7. Shares are up 111.5% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Herbalife a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Herbalife as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Herbalife Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Biogen Idec ( BIIB) is up $5.73 (2.0%) to $296.70 on average volume. Thus far, 504,701 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $290.52-$298.82 after having opened the day at $291.71 as compared to the previous trading day's close of $290.97.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $69.4 billion and is part of the health care sector. The company has a P/E ratio of 41.3, above the S&P 500 P/E ratio of 17.7. Shares are up 100.7% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Credit Suisse Surges After Strong Q1, Record Wealth Management Inflows

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Global Stocks Slide as Yield Pressure, Commodity Surge Prompts Equity Exit

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday